Por: MarketWatch Business August 31, 2023
The Cambridge, Mass., company on Thursday said it expects the reorganization, which also includes the departure of a trio of top executives, will result in annual savings of about $240 million and extend its cash runway into 2026. Sage currently has nearly 700 employees, according to data from FactSet. The FDA earlier this month approved Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major... + full article
MarketWatch USA Business August 31, 2023
The Cambridge, Mass., company on Thursday said it expects the reorganization, which also includes the departure of a trio of top executives, will result in annual savings of about $240 million and extend its cash runway into 2026. Sage currently has nearly 700 employees,... + más
Sage Therapeutics Cutting 40% of Staff in Restructuring >SAGE | MarketWatch
FDA sets a decision date for Sage’s postpartum depression pill | The Boston Globe
The Boston Globe USA Business August 07, 2023
A pair of Cambridge drug makers Monday postponed setting a price for their newly approved pill to treat postpartum depression as they weighed the financial impact of a US regulatory decision to reject the pill’s use for the more widespread condition of major depressive... + más
Mom goes viral sharing reality of her postpartum body | ABC News
Kylie Jenner reveals she had postpartum depression twice | ABC News
The Boston Globe USA Business February 06, 2023
An experimental drug that in a clinical trial helped some women quickly recover from postpartum depression could be approved by federal regulators by Aug. 6. The medicine, developed by Sage Therapeutics, is poised to become the first pill for the condition, which afflicts as... + más
A pill for postpartum depression is on the horizon | The Boston Globe
I wanted to put a knife into my baby: Moms on their postpartum psychosis | Newsweek
RTTNews USA Health January 18, 2023
This commercial-stage biotechnology company developing next-generation, targeted antibody drug conjugates is aiming to achieve double-digit year-over-year revenue growth for its lead drug.The company we are profiling today is ADC Therapeutics SA () and the drug in focus is... + más
Nkarta | RTTNews
Chicago White Sox pitcher Liam Hendriks says he will undergo cancer treatment after being diagnosed with non-Hodgkin's lymphoma | CBS News
The Boston Globe USA Nation December 29, 2022
A new coronavirus variant dubbed XBB has swiftly spreading in the Northeast, jumping from about 35 percent of cases during the week ending Dec. 17 to just over half of cases last week, according to .Here’s a quick primer on what we know about the variant.It is more... + más
Highly Immune Evasive Omicron XBB.1.5 Variant Is Quickly Becoming Dominant in U.S. as It Doubles Weekly | NBC 6 South Florida
Highly immune evasive omicron XBB.1.5 variant is quickly becoming dominant in U.S. as it doubles weekly | CNBC
WPTV USA Nation November 30, 2022
If you or someone you love deals with a chronic disease, you're likely aware of injections. New research is indicating that in the not-too-distant future, that same medication and routine vaccinations might come in a pill form.For 10 years, biotech company has been working... + más
Op-Ed: Fentanyl pill producers used to mimic other pharmaceuticals, now they don't have to | Los Angeles Times
Hey FDA, Free the Birth Control Pill! | The Daily Beast
The Boston Globe USA Business October 12, 2022
Competition is heating up among biotech startups building technologies that improve or expand upon what gene editing can do. While most of these firms are devising therapies that permanently modify DNA to treat, and potentially cure, genetic diseases, a growing number think that... + más
Tech insiders have a lot to say about the local startup scene. Most of it is good. | The Boston Globe
See the presentations that hot healthcare startups used to raise millions from top VCs | Business Insider
About iurex | Privacy Policy | Disclaimer |